Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813910 | 0.91 | GAA (0.37) | ESR2GAATSHRALDH1A1KDM4E | |
| SCHEMBL9894281 | 0.90 | GAA (0.33) | ESR2GAAARTSHRALDH1A1 | |
| SCHEMBL840396 | 0.88 | GAA (0.36) | ESR2GAATSHRALDH1A1KDM4E | |
| SCHEMBL18411232 | 0.81 | GAA (0.43) | GAATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL28213045 | 0.75 | TSHR (0.38) | ESR2GAATSHRKDM4E | |
| SCHEMBL28043669 | 0.75 | TSHR (0.38) | ESR2GAATSHRALDH1A1KDM4E | |
| SCHEMBL841741 | 0.75 | ESR2 (0.32) | ESR2TSHR | |
| SCHEMBL28573262 | 0.75 | AR (0.33) | GAAARTSHRALDH1A1KDM4E | |
| SCHEMBL1760270 | 0.74 | ALDH1A1 (0.38) | GAATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL5166207 | 0.74 | ALDH1A1 (0.35) | ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765358-B1 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7652000-B2 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1765358-A2 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060009422-A1 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005123094-A2 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009422-A1 | Boron-containing compounds and methods of use | BROX, BTD, PBDC1 | ESR2 436/4885GAA 1146/4885AR 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.